Invention Grant
US08435532B2 Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis
有权
修饰细胞外基质蛋白在动脉粥样硬化诊断和治疗中的应用
- Patent Title: Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis
- Patent Title (中): 修饰细胞外基质蛋白在动脉粥样硬化诊断和治疗中的应用
-
Application No.: US13569051Application Date: 2012-08-07
-
Publication No.: US08435532B2Publication Date: 2013-05-07
- Inventor: Jan Nilsson
- Applicant: Jan Nilsson
- Applicant Address: US CA Torrance
- Assignee: CardioVax, LLC
- Current Assignee: CardioVax, LLC
- Current Assignee Address: US CA Torrance
- Agency: K&L Gates LLP
- Agent Louis C. Cullman; Michelle Glasky Bergman
- Priority: SE0400683 20040319
- Main IPC: A61K39/00
- IPC: A61K39/00
Abstract:
The present invention relates to the use of fibronectin, tenascin, collagens type I, III, VI and/or VIII modified by aldehyde or by glycosylation in ELISA for detection of antibodies in plasma and serum to diagnose atherosclerosis as well as the use of induction of tolerance and active as well as passive immunization against glycosylated or aldehydemodified fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis.
Public/Granted literature
- US20120301491A1 Use of Modified Extracellular Matrix Proteins in Diagnosis and Treatment of Atherosclerosis Public/Granted day:2012-11-29
Information query
